Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,321.55
    +153.48 (+0.38%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,860.60
    +1,362.36 (+1.96%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,534.08
    +3.48 (+0.23%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Blueprint Medicines: 2Q Earnings Snapshot

Blueprint Medicines: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $27 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.31 per share.

The cancer drug developer posted revenue of $41.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $3.2 million.

Blueprint Medicines shares have fallen 21 percent since the beginning of the year. The stock has increased 14 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC